Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")

Inclusion Criteria: * All participants: ≥18 years, male or female (non-WOCBP only), BMI 18-35 kg/m² (inclusive); no increased risk of bleeding or common causes of bleeding, no liver dysfunction; no CYP3A4 inhibitors/inducers; * Participants with reduced kidney function including those on kidney replacement therapy ("dialysis"): stable disease stratified by renal function (mild, moderate, severe, ESRD), no recent cardiovascular events; * Age-, gender- and weight-matched participants: normal kidney function, stable and well controlled hypertension and dyslipidemia acceptable, no medications influencing the coagulation system. Exclusion Criteria: Subjects with renal impairment * Acute renal failure or active nephritis. * Known impaired hepatic function. * History of definite myocardial infarction or cerebrovascular accident within the six months prior to the screening visit. * History of vascular surgery or intervention (e.g., coronary artery bypass, percutaneous transluminal angioplasty etc.) less than 6 months prior to dosing. * Congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring antiarrhythmic treatment. * Any other disease or condition which could influence the physiological metabolic turnover (e.g., endocrine diseases, severe infections). Age-, gender, weight matched subjects \- History of relevant diseases of vital organs or systems (e.g., of the central nervous system or other systems or organs) with the exception of m…